Glenmark sees minimal impact of FDA action on narcotic drugs
This article was originally published in Scrip
Executive Summary
Glenmark expects the recent US FDA action, calling for the ending of production and distribution of 14 unapproved narcotic drugs, including morphine, to have little impact on its financial performance.